—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Roche Holding AG (ROP.SW) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ROP.SW, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index AI Users — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

AI Users · as of 2026-10-23

DayWeekMonth3 months
ROP.SW−0.3%+3.1%+7.6%+6.3%
Research, Design & Development−1.0%+3.0%+5.4%—
AI Users−1.2%+1.1%+6.6%—

Against the index: 2.0 pts ahead on the week, 1.0 pts ahead on the month; against its Research, Design & Development sleeve 2.2 pts ahead on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 46, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-23
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 81th percentile of the window, -14.3% over 20 sessions. Factor regime → 2026-10-23
  • Sector × region Health care in Europe: +3.9% week · +8.0% month · +1.3% quarter · +8.6% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-24
  • Sovereign pressure Index -1.16 · down 1.91 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-23
Who it is priced against AI Users · Research, Design & Development · 3 names with week and year-to-date

Peer group

AI Users · Research, Design & Development

Compared against ROP.SW on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Roche Holding AG

ROP.SW in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Roche Holding AG develops and sells medicines and diagnostic tests across many regions, treating areas such as cancer, infectious disease, and neurological disorders. It also produces diagnostic instruments and digital health tools, and runs research partnerships to explore new treatment targets. The company is based in Basel, Switzerland.
Where it sits in the stack
In the AI Users index, which tracks firms deploying AI to strengthen existing businesses, Roche sits in the Research, Design & Development section. Inside Roche, this covers using AI for discovery work, treatment engineering, running experiments, and developing new products, not as a supplier to any build-out layer.
Who it is priced against
Closelooknet's peer group places Roche with other drugmakers applying AI to research, Eli Lilly and Natera, grouped under the same AI Users research-and-development reading. The market also commonly compares it with Novartis as a close pharmaceutical peer.
Why Closelooknet tracks it
Roche holds a seat in the AI Users index under Research, Design & Development, its only index placement in the diary's coverage. It does not yet carry a Closelooknet score, so no module can be named stronger or weaker than another. No edition of the diary has quoted it so far.
What the diary watches
The diary watches whether Roche's reported use of AI in drug discovery and experiment design shows up in new product announcements, which would deepen its place in the Research, Design & Development section.

Roche Holding AG (ROP.SW) trades on the SW exchange in Switzerland, classified under Healthcare.

The Closelooknet company score reads 56/100 composite (momentum 79, quality 84, valuation 56) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-10-24. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 2.51%, annual · buybacks 987 m CHF in FY2025

Dividends and capital return

What ROP.SW pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 9.80 CHF per share · a 2.51% yield on the 2026-10-23 close 1 distribution, paid once a year 2026-10-23
  • Change on the year +1.0% against the prior twelve months prior twelve months 9.70 CHF per share
  • Last distribution 9.80 CHF per share as the price series records it, within days of the ex-date 2026-03-12
  • By calendar year 2025: 9.70 CHF (partial) · 2026: 9.80 CHF to date first distribution recorded in the three-year window: 2025-03-27
  • Dividends paid, FY2025 8.39 bn CHF 64% of earnings
  • Buybacks, FY2025 987 m CHF 0.3% of today's market value
  • Share count +0.1% in FY2025 857 m CHF of stock-based compensation in the year
  • Capital returned 9.37 bn CHF · 67% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-24

Quick answers

What is Roche Holding AG (ROP.SW)?

Roche Holding AG trades as ROP.SW on the SW exchange (Switzerland) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-24.

Is ROP.SW in a Closelooknet index?

Not currently — Roche Holding AG is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-24.

What is Roche Holding AG's Closelooknet composite score?

56 out of 100, with momentum 79, quality 84 and valuation 56 sub-scores, as of 2026-10-24. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does ROP.SW trade against its moving averages?

Uptrend stack intact: Trades +8% vs the 50-day and +14.9% vs the 200-day average, 1% below the 52-week high and +56% off the 52-week low. Computed from daily closes. As of 2026-10-23 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is ROP.SW doing against its Closelooknet index?

Over the past month Roche Holding AG is +7.6% against +6.6% for the AI Users — 1.0 points ahead of its index, as of 2026-10-23. Its Research, Design & Development sleeve is +5.4% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Roche Holding AG compare with its peers?

Against its peer group (AI Users · Research, Design & Development), Roche Holding AG (ROP.SW) sits 1.0% below its 52-week high, 8.0% above its 50-day average; Eli Lilly and Company (LLY) is 3.6% below, Natera Inc (NTRA) is 7.6% below, AstraZeneca PLC (AZN.L) is 17.1% below. Put any of them next to ROP.SW in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Roche Holding AG do?

Roche Holding AG develops and sells medicines and diagnostic tests across many regions, treating areas such as cancer, infectious disease, and neurological disorders. It also produces diagnostic instruments and digital health tools, and runs research partnerships to explore new treatment targets. The company is based in Basel, Switzerland. Closelooknet's peer group places Roche with other drugmakers applying AI to research, Eli Lilly and Natera, grouped under the same AI Users research-and-development reading. The market also commonly compares it with Novartis as a close pharmaceutical peer.

Where does Roche Holding AG sit in the AI build-out?

In the AI Users index, which tracks firms deploying AI to strengthen existing businesses, Roche sits in the Research, Design & Development section. Inside Roche, this covers using AI for discovery work, treatment engineering, running experiments, and developing new products, not as a supplier to any build-out layer. Roche holds a seat in the AI Users index under Research, Design & Development, its only index placement in the diary's coverage. It does not yet carry a Closelooknet score, so no module can be named stronger or weaker than another. No edition of the diary has quoted it so far.

Does Roche Holding AG pay a dividend?

Roche Holding AG has paid 9.80 CHF per share over the last twelve months, paid once a year, a trailing yield of 2.51% on the 2026-10-23 close; the last distribution recorded in the price series was 9.80 CHF on 2026-03-12. In fiscal 2025 the company paid 8.39 bn CHF in dividends and bought back 987 m CHF of its own shares, 67% of that year’s free cash flow. The share count rose 0.1% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ROP.SW, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe